Merck submits Keytruda for bladder cancer
Merck & Co is continuing on its quest to expand the approved uses of its immunotherapy Keytruda, filing the drug in the US for both first- and second-line use in bladder cancer.
Read More
Tag: 1185762
- European life sciences coalition launched to boost investment ecosystem
- 99mtc‑maraciclatide granted fast track status for ILD imaging
- Bioxytran reports rapid viral clearance in phase 2 trial
- Thx Pharma and Biocodex sign rare disease licensing deal
- AstraZeneca bladder cancer therapy wins NICE backing
